---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-040209"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2022-03-30T23:59:59+00:00"
generated_at: "2026-06-26T13:37:40.880328+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics CEO Lucy Lu resigns; COO David Jin becomes interim principal executive officer

## Summary
- Lucy Lu, M.D. resigned as President, CEO, and Board member effective March 31, 2022, to pursue an outside opportunity.
- She entered into a consulting arrangement with the Company effective March 31, 2022.
- David Jin, previously COO, will serve as interim principal executive officer from March 31, 2022.
- Company continues evaluating potential strategic transaction options.

## SEC filing metadata
- accession: 0001104659-22-040209
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2022-03-30T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/tm2210898d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-040209
- JSON: https://secwatch.observer/filing/0001104659-22-040209.json
- Plain text: https://secwatch.observer/filing/0001104659-22-040209.txt

## Key facts
- Executive change
  David Jin was appointed as interim principal executive officer at AVENUE THERAPEUTICS, INC..
  - Action: appointed
  - Role: interim principal executive officer
  source text: David Jin, who was previously serving as the Company’s Chief Operating Officer, will begin acting as the Company’s interim principal executive officer as of March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm
- Executive change
  Lucy Lu resigned as President and Chief Executive Officer at AVENUE THERAPEUTICS, INC..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Lucy Lu, M.D. notified Avenue Therapeutics, Inc. (the “Company”) that she was resigning from her role as the Company’s President and Chief Executive Officer, and from her position as a member of the Company’s Board of Directors, effective in each case as of March 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.